{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:26:03Z","timestamp":1788823563326,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:00:00Z","timestamp":1793836800000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["U19AI117950"],"award-info":[{"award-number":["U19AI117950"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SCR_022380"],"award-info":[{"award-number":["SCR_022380"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016520"],"award-info":[{"award-number":["P30 CA016520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI045008"],"award-info":[{"award-number":["P30 AI045008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymthe.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:52:09Z","timestamp":1754441529000},"page":"5556-5571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy"],"prefix":"10.1016","volume":"33","author":[{"given":"Divanshu","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasikanth","family":"Manne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. John","family":"Wherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.002_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging Cellular Therapies for Cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.08.002_bib3","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2025.08.002_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.08.002_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.cgt.7700710","article-title":"A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells","volume":"11","author":"Moeller","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib9","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib11","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.002_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.08.002_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.08.002_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557405","article-title":"Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL","volume":"16","author":"Bols\u00e9e","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib15","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.08.002_bib16","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib18","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.08.002_bib19","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2025.08.002_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.08.002_bib23","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2019-131056","article-title":"A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib24","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.002_bib25","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2019-123424","article-title":"Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia (r\/r B-ALL): Amelia Study","volume":"134","author":"Amrolia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib26","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib27","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib28","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib29","article-title":"CD19 CAR Therapy for Acute Lymphoblastic Leukemia","volume":"35","author":"Sadelain","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ymthe.2025.08.002_bib30","article-title":"CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.08.002_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","article-title":"Targeting CD22 for B-cell hematologic malignancies","volume":"12","author":"Xu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib32","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1080\/10428194.2023.2243357","article-title":"Differences in efficacy and safety among CAR-Ts anti-CD19\/CD22, anti-CD19, and anti-CD22, in adult patients with relapse\/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review","volume":"64","author":"Becerril-Rico","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2025.08.002_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178403","article-title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","volume":"14","author":"Fergusson","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib34","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.08.002_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.002_bib39","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib40","doi-asserted-by":"crossref","first-page":"11790","DOI":"10.1073\/pnas.162359999","article-title":"Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors","volume":"99","author":"Riley","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.002_bib41","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.08.002_bib42","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.002_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2025.08.002_bib44","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","article-title":"A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq","volume":"28","author":"Boroughs","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2025.08.002_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.08.002_bib48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/cr.2010.161","article-title":"A single NF\u03baB system for both canonical and non-canonical signaling","volume":"21","author":"Shih","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2025.08.002_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cytogfr.2008.04.005","article-title":"Crosstalk via the NF-\u03baB signaling system","volume":"19","author":"Basak","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2025.08.002_bib51","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1074\/jbc.M409492200","article-title":"Role for protein kinase Ctheta (PKCtheta) in TCR\/CD28-mediated signaling through the canonical but not the non-canonical pathway for NF-kappaB activation","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.08.002_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000448","article-title":"The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells","volume":"2","author":"Paulos","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib53","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.4049\/jimmunol.176.9.5652","article-title":"STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice","volume":"176","author":"Cho","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib54","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib55","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.002_bib56","article-title":"Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors","volume":"2","author":"Muliaditan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.08.002_bib58","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib59","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.08.002_bib60","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41591-024-02882-2","article-title":"Author Correction: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"30","author":"Stephan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.08.002_bib62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib63","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.08.002_bib66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.08.002_bib67","article-title":"Rab5 Overcomes CAR T Cell Dysfunction Induced by Tumor-Mediated CAR Capture","author":"Gu","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2025.08.002_bib68","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.08.002_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2017.11.001","article-title":"Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium","volume":"8","author":"Medvec","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.08.002_bib70","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib71","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006613","article-title":"Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor","volume":"13","author":"Leibman","year":"2017","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2025.08.002_bib73","article-title":"Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque","volume":"3","author":"Ellis","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.08.002_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181576","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"134","author":"Tebas","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.002_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011853","article-title":"Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells","volume":"19","author":"Zhou","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2025.08.002_bib76","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/2326-6066.CIR-24-1347","article-title":"CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target","volume":"13","author":"Shukla","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.08.002_bib77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.002_bib78","article-title":"Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry","volume":"484\u2013485","author":"Maldini","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymthe.2025.08.002_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101954","article-title":"Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures","volume":"4","author":"Selli","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.ymthe.2025.08.002_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.08.002_bib81","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.08.002_bib82","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2025.08.002_bib83","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500632X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500632X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:25:43Z","timestamp":1779524743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500632X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S152500162500632X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}